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esponsibility of InstAbstract Abdominal aortic aneurysm (AAA) is an inﬂammatory vascular disorder with high mortality.
Accumulating evidence shows that toll-like receptor 2 (TLR2) plays a critical role in the regulation of
wound-repairing process after tissue injury. We wondered if TLR2 signaling contributed to the
pathogenesis of AAA and that targeting TLR2 would attenuate AAA development and progression. In
this study, enhanced expression of TLR2 and its ligands were observed in human AAA tissue.
Neutralization of TLR2 protected against AAA development and caused established AAA to regress in
mouse models of AAA. In addition, TLR2-deﬁcient mice also failed to develop AAA. The prophylactic
and therapeutic effects of blocking TLR2 were accompanied by a signiﬁcant resolution of inﬂammation
and vascular remodeling, as indicated by the decreased expression or activity of MMP-2/9, α-SMA,
inﬂammatory cytokines, and transcription factors NF-κB, AP-1 and STAT1/3 in AAA tissue. Mechan-
istically, blocking TLR2 decreased the expression and interaction of TLR2 and several endogenous7
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TLR2 and abdominal aortic aneurysm 177ligands, which diminished chronic inﬂammation and vascular remodeling in the vascular tissue of AAA.
Our studies indicate that the interactions between TLR2 and its endogenous ligands contribute to the
pathogenesis of AAA and that targeting TLR2 offers great potential toward the development of
therapeutic agents against AAA.
& 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Abdominal aortic aneurysm (AAA), which is characterized by
chronic transmural inﬂammation and destructive remodeling of the
vascular wall, results in dilation, triggers clinical complications, and
eventually ruptures to lead to high morbidity and mortality1.
Although the pathogenesis of AAA formation and progression
remains poorly understood, chronic inﬂammation, enzymatic degra-
dation of elastin and collagen, and malignant vascular remodeling
constitute the prominent pathological changes associated with AAA2.
Currently, the primary therapeutic strategies are surgical procedures,
especially for large AAAs, including replacement of the damaged
aorta with an artiﬁcial vascular graft or conducting endovascular stent
graft repair. However, considering the risk of endoleaks, graft
displacement, postoperative survival rates of the endovascular stent
and the high risk of open repair, surgery must be restricted to within
narrow limits3. Therefore, more effective therapeutic alternatives for
the management of AAAs are necessary.
Recent work suggests that innate and adaptive immune
responses participate in the pathogenesis of AAA4,5. Vascular
inﬂammation may result from a wide variety of insults, including
infection, oxidative stress and chemotherapeutic agents. Persistent
or repeated insulting stimuli activate and sustain the tissue wound-
healing process in blood vessels. The host response to these insults
is intricately directed toward recognizing pathogen-associated
molecular patterns (PAMPs), which are produced by pathogenic
organisms, or damage-associated molecular patterns (DAMPs),
which are released from damaged tissues through an interaction
with pattern recognition receptors (PRRs) on immune and residual
cells. These endogenous DAMPs, including high-mobility group
box 1 (HMGB1), heat shock proteins (HSPs), S100 family, uric
acid and adenosine, can activate immune responses and participate
in the development and progression of vascular diseases6,7.
Interestingly, these endogenous factors may also act as
resolution-associated molecular patterns (RAMPs) to promote the
resolution of inﬂammation and injured tissues8,9. Activation of
PRRs by DAMPs also initiates and shapes adaptive immune
responses by activating antigen-presenting cells and recruitment of
T and B cell subsets10. For instance, Shimizu et al.11 found that
there was a shift toward type 2 T help (Th2) cell responses in
human AAAs compared with stenotic atheromas, while the
balance of Th1/Th2 cytokines has an important regulatory role
in modulating matrix remodeling, which has been implicated in the
pathogenesis of AAAs and arteriosclerosis.
Pryshchep et al.12 reported that the vessel-speciﬁc risk for inﬂam-
matory vasculopathies is partly because of distinct toll-like receptor
(TLR) proﬁles and subsequent wall-inﬁltrating T cell responses. TLR2
is ubiquitously present in the aorta, and enhanced TLR2 expression has
been described in human atherosclerotic lesions13. Moreover, TLR2
activation plays a central role in the regulation of inﬂammation after
chronic tissue injury, which leads to tissue ﬁbrosis in many organs,including the aorta14. Indeed, the underlying mechanisms of aneurysm
involve a complex vascular remodeling. We recently found that
targeting TLR2 prompts the resolution of chronic inﬂammation and
protects against doxorubicin-induced cardiovascular remodeling and
dysfunction15. We thus hypothesized that TLR2 signaling might
involve in the pathogenesis of AAA. Our studies demonstrate that
TLR2 activity critically participates in the pathogenesis of AAA and
that targeting TLR2 signaling may have therapeutic potential against
AAA formation and progression.2. Materials and methods
2.1. Acquisition of human aortic samples
Human aortic aneurysm and control tissues were obtained from
AAA patients who received an open surgical repair process. For
immunoﬂuorescence analysis, frozen sections (8 μm) of aortic
samples were incubated with anti-human TLR2 (eBioscience Inc.)
and HMGB1 (Sigma-Aldrich), followed by Alexa Fluor 488- and
647-conjugated IgG. For ex vivo organ cultures of human aortic
specimens, fresh tissues were divided into 1 mm segments and
cultured in DMEM with 1% BSA in a 24-well plate as described
previously16. The conditioned media was collected after the tissue
was treated with or without 20 μg/mL of TLR2ab for 4896 h. The
activities of matrix metalloproteinase-2/9 (MMP-2/9) were deter-
mined by gelatin zymography with an equal volume of conditioned
media. All protocols using human specimens were approved by the
Institutional Review Board of Chinese Academy of Medical
Sciences and Peking Union Medical College. The study conforms
to the principles outlined in the Declaration of Helsinki.
2.2. Animals and materials
Male C57BL/6 mice (6–8 weeks) were purchased from Vital River
Inc. (Beijing, China). Tlr2 / mice (C57BL/6 background and
backcrossed more than 9 times to the C57BL/6 background),
Apoe / mice and corresponding wide-type (WT) mice were
obtained from Jackson Laboratories (Bar Harbor, USA). TLR2-
neutralizing mAb was purchased from R&D System Inc. (Min-
neapolis, USA). Angiotensin (Ang) II was obtained from Sigma-
Aldrich (St. Louis, USA). ALZET osmotic pumps were purchased
from DURECT Corporation (Cupertino, USA).
2.3. Generation of AAA models
A CaCl2-induced mouse AAA model was generated by periaortic
application of 0.5 mol/L CaCl2 according to the procedures described
previously17,18. Each mouse was anesthetized with sodium pentobarbi-
tal (45 mg/kg, i.p.) before surgically exposing the abdominal aorta and
inferior vena cava. For the prevention study, mice were randomly
Huimin Yan et al.178divided into each group (n¼12–15). In the sham group, the aorta was
treated with saline instead of CaCl2. As positive controls, mice were
treated with doxycycline (30 mg/kg, p.o.) daily for 6 weeks. Mice were
treated with either TLR2-neutralizing antibody (TLR2ab) or isotype-
IgG (200 μg/kg, i.v.) on days 1, 3 and 7 after CaCl2 application and
then weekly for 6 weeks. Mice (n¼10/group) were randomly assigned
to receive ultrasonography. For the regression study, AAA was
generated by periaortic administration of 0.5 mol/L of CaCl2 (n¼15)
or saline (n¼11). Abdominal aortic ultrasonography was performed 6
weeks after CaCl2 administration to conﬁrm AAA formation. Mice
with well-established AAA were randomly treated with TLR2ab
(200 μg/kg, i.v.) or saline for additional 6 weeks. In the end of study,
mice (n¼8/group) were randomly assigned to receive ultrasonography.
To generate an Ang II-induced AAA model, six-month-old
Apoe / male mice were administered saline or Ang II
(1000 ng/kg/min) via Alzet osmotic minipumps (Durect Corporation,
Cupertino, USA) for 28 days to induce suprarenal aneurysms as
described previously19. Brieﬂy, mice were anaesthetized intraperitone-
ally using sodium pentobarbital (45 mg/kg), and the pumps were
placed into the subcutaneous space of the mice through a small incision
in the back of the neck.
2.4. Morphometric analysis
Mice were anesthetized with sodium pentobarbital (40–50 mg/kg, i.p.)
and the aortas were immediately perfused with saline or 4% parafor-
maldehyde for half an hour20. The external diameter was measured
based on the images of ﬁxed-aortas and lumen diameter was examined
by measuring the lumen perimeters of cross sections of parafﬁn-
embedded aortas using Image-Pro Plus software (Media Cybernetics).
2.5. Ultrasonography
Mice were anesthetized with sodium pentobarbital (40–50 mg/kg,
i.p.). The ultrasound imaging system Visual Sonics Vevo 770
(Visual Sonics, Canada) was used to perform B- and M-mode
imaging of the abdominal aorta. The abdominal aorta was located
using anatomical landmarks and Doppler signals were used to
conﬁrm the identiﬁcation of the abdominal aorta. A longitudinal
image of the abdominal aorta between the left renal arteries and the
iliac bifurcation was acquired and recorded for at least 8–10
cardiac cycle in B-mode and M-mode. To get excellent reprodu-
cibility, the maximal diameter and other parameters were mea-
sured, rescanned and remeasured at least ﬁve different locations by
two individuals blinded to the groups.
2.6. Histology and immunohistochemistry
Formaldehyde-ﬁxed parafﬁn sections (3 μm) were stained for general
structure (hematoxylin and eosin, H&E), elastin (Verhoeff van Gieson,
VVG), collagen I/III (picrosirius red), macrophages (CD11b), T cells
(CD4), myoﬁbroblasts (α-smooth muscle actin, α-SMA) and cytokines.
Picrosirius-stained sections were imaged by ordinary polychromatic
and polarized light microscopes using identical shutter conditions21. All
images were acquired using the same exposure time and loaded into
the Image-Pro Plus software for analysis. The positive staining was
highlighted red color by the same threshold (hue, saturation and
brightness). The region of the labeled red were measured and analyzed
in a blinded way. Data were obtained from 5–8 serial cross-sections, 8
aortas per treatment, and presented as the integrated optical density
(IOD). For each section, data were presented as averages from at least8 non-overlapping images. Species- and isotype-matched IgG was used
as a negative control.
2.7. Immunoﬂuorescence
Frozen sections (8 μm) were ﬁxed in cold formaldehyde for
5 min, rinsed twice in PBS (pH 7.4), and blocked with 3%
BSA, processed as described22. The sections were incubated with
indicated primary and secondary antibodies and observed under an
E2000U confocal microscope or ﬂuorescent microscopy and
evaluated using Image-Pro Plus software.
2.8. ROS analysis
To evaluate ROS production in aortic tissues from mice treated
with or without Ang II, the abdominal aortas were harvested, snap-
frozen and embedded in optimal cutting temperature compound.
The sections (10 μm) were incubated with dihydroethidine hydro-
chloride (5 μmol/L) (Molecular Probes, USA) at 37 1C for 30 min
and covered with DAPI solution. ROS content (red ﬂuorescence)
was detected with confocal microscopy.
2.9. Western blot
The aorta was homogenized and centrifuged at 14,000 g at 4 1C
20 min to collect protein extract as previously described23.
2.10. Gelatin zymography
Aortic protein was extracted as described and 20 μg proteins were
separated on 12% SDS-PAGE gels containing 1 mg/mL gelatin
under nonreducing conditions. After electrophoresis, the gel was
soaked in renaturing buffer and equilibrated in developing buffer.
The gel was incubated in fresh developing buffer overnight at
37 1C. Then the gels were stained with 0.5% Coomassie blue
R250 and destained in 25% methanol/20% acetic acid.
2.11. Statistics
Data are expressed as mean7SD and analyzed with SPSS software
version 11.0 (SPSS Inc.). For statistical analysis, comparisons
between groups were performed using one-way ANOVA with the
LSD test or a nonparametric Mann-Whitney U test if the data were
not normally distributed. A Kaplan-Meier analysis summarized the
survival rate. Statistical signiﬁcance was accepted at Po0.05.3. Results
3.1. Human AAA vascular tissue over-expresses TLR2 and TLR2
ligands
Although TLR2 has been linked with several forms of cardiovascular
disease, no direct evidence suggests a role for TLR2 in the
development of AAA. We examined the expression of TLR2 and
its endogenous ligands in human AAA tissue obtained from patients
who received an open surgery repair. Detailed descriptions of these
patients including age, gender, and average aortic aneurysm diameters
et al. were shown in Table S1 in Supporting information. Human
AAA tissue manifested the characteristic morphologic changes, such
as local elastin degeneration, accumulation of necrotic cells, intra-
Figure 1 TLR2 and its endogenous ligands are up-regulated in human AAA. (A) Representative H&E staining of human AAA or control
abdominal aortic tissue. (B and C) The expression of TLR2, HMGB1, HSP70 and S100A8 was detected by Western blot (n¼5/group). Data are
means7SD. #Po0.05, ##Po0.01, ###Po0.001, compared to control group. (D) The expression of TLR2 was detected by immunoﬂuorescence
(TLR2, FITC, green; DNA, DAPI, blue). (E) The colocalization of TLR2 and HMGB1 (TLR2, Alexa 488, green; HMGB1, Alexa 647, red; and
DNA, DAPI, blue). (F and G) Blocking TLR2 attenuated the activity and expression of NF-κBp65 and HMGB1 detected by Western blot (F), and
the MMP-2/9 activity in conditioned media in vitro cultured human AAA tissue detected by gelatin zymography (G). Representative images of
Western blot or gelatin zymography are shown with quantitative analysis (n¼5/group).
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TLR2 and its endogenous ligands, including HMGB1, HSP70 and
S100A8, were up-regulated in human aneurysm tissue compared to
the control aortic tissue (Fig. 1BD). Moreover, TLR2 and HMGB1
were found to co-localize in adventitia and outer media (Fig. 1E),
suggesting a potential interaction between TLR2 and HMGB1.
Indeed, blocking TLR2 attenuated the expression or activation of
inﬂammatory factors NF-κB and HMGB1 in human AAA tissue and
the activity of secreted MMP-2/9 in conditioned media of cultured
human AAA tissue (Fig. 1F and G). These data indicate that TLR2
signaling may play a crucial role in the pathogenesis of human AAA.
3.2. Targeting TLR2 protected mice from developing CaCl2-
induced AAA
We recently found that TLR2 activity is critically involved in the
regulation of the injury repair process after acute tissue injury23,24.
We suspected whether antagonizing TLR2 would protect animals
from CaCl2-induced AAA. We found that blocking TLR2 activity
using a TLR2ab attenuated the dilation of aneurysm compared to
vehicle control (1.1470.31 versus 1.6970.49; Po0.01; Fig. 2A)
or with isotype-IgG (1.1470.31 versus 1.5970.38; Po0.01;
Fig. 2A). In addition, doxycycline, a non-speciﬁc MMP inhibitor,
as a positive control25, showed a similar protective role as TLR2ab
compared to vehicle control (1.1570.43 versus 1.6970.49;
Po0.01; Fig. 2A). The data of maximum external diameter from
ultrasound also conﬁrmed these results (Fig. 2B, data not shown).
The CaCl2-damaged aorta was characterized by low elastin content
and ﬂattening and fragmentation of naturally wavy elastic lamel-
lae. TLR2ab and doxycycline treated mice relatively preserved
elastic laminar integrity and waviness (Fig. 2C and D). Using the
morphometry of H&E staining of cross sections, we found that
CaCl2 induced a time-dependent increase in the internal aortic
diameters (data not shown), while the expansion of internal aortic
diameter was signiﬁcantly reduced after 6 weeks of treatment with
TLR2ab (0.4670.06 versus 0.5770.05; Po0.01; Fig. 2E). These
data suggest that blocking TLR2 protects against the development
of CaCl2-induced AAA.
Excess expression and activation of MMP-2/9 has been found to
contribute to the destructive remodeling of extracellular matrix in
AAA18. Targeting TLR2 attenuated the expression (Fig. 3A) and
activation (Fig. 3B) of MMP-2/9. After tissue injury, a wound-healing
response was activated; the fate of recruited/activated ﬁbroblasts in
injured tissues may ultimately determine whether normal healing or
end-stage ﬁbrosis occurs. Indeed, the expression of α-SMA, a marker
for myoﬁbroblasts26, was signiﬁcantly increased in a time-dependent
manner. The α-SMA-positive cells migrated to and surrounded the
lesion sites within two weeks and stayed there for 12 weeks after
CaCl2 application (Fig. 3C) with collagen I/III accumulation. How-
ever, targeting TLR2 reduced α-SMA-positive cells in adventitia (data
not shown), α-SMA expression (Fig. 3D), and protected against
deposition of collagen I/III (Fig. 3E). These observations indicate that
blocking TLR2 attenuates vascular ﬁbrosis and remodeling in CaCl2-
induced AAA.
3.3. Targeting TLR2 ameliorated CaCl2-induced AAA
To determine the potential therapeutic signiﬁcance of TLR2 in
AAA development, the mice with established AAA were treated
with or without TLR2ab for 6 weeks. We found that therapeutic
antagonism against TLR2 resulted in a decreased external aorticdiameter of AAA compared to the vehicle control, as detected
by morphometry (1.0870.232 versus 1.3870.375; Po0.01;
Fig. 4A and C) and by ultrasonography (data not shown), while
the expansion of the internal aortic diameters of AAA was also
inhibited compared to vehicle control (0.5170.101 versus
0.6170.048; Fig. 4C), indicating that blocking TLR2 attenuated
the luminal expansion. Furthermore, elastic laminar integrity and
waviness were preserved in TLR2ab-treated mice (Fig. 4E). These
data suggested that therapeutic blocking of TLR2 inhibits elastin
degeneration and attenuates aneurismal remodeling, leading to a
regression of established AAA.
To validate the crucial roles of TLR2 in AAA development,
Tlr2 / and WT mice were subjected to CaCl2-induced AAA. We
found that TLR2 deﬁciency prevented CaCl2-induced dilation of
the aorta compared to WT mice, as illustrated in Fig. 4B and D
(0.9570.12 versus 1.3370.27; Po0.05). Compared to WT mice,
Tlr2 / mice showed a much smaller internal aortic diameter, as
measured by the lumen perimeters of aortic cross sections
(0.4570.11 versus 0.5870.05; Po0.05; Fig. 4D). Histological
study with VVG staining revealed that a deﬁciency of TLR2
protected from aortic dilation and elastin degradation in media and
exhibited a signiﬁcant increase in the elastin content of aortas
compared to that from WT animals (Fig. 4F).3.4. Targeting of TLR2 reduced the expression of TLR2 and
TLR2 ligands in vascular tissue
Periaortic application of CaCl2 resulted in a time-dependent increase of
TLR2þ cells in AAA and targeting TLR2 reduced the accumulation of
TLR2þ cells in aortic tissues (Fig. 5A). Furthermore, TLR2þ cells co-
localized with inﬁltrating CD11bþ macrophages in adventitia of the
injured aortas, and the expression of TLR2 on CD11bþ macrophages
was up-regulated after CaCl2 application (Fig. 5B). The HMGB1
bound to TLR2 in the adventitia and outer media of aortic walls from
AAA aortas (Fig. 5C), but was not detected in the control aorta (data
not shown), indicating that this endogenous TLR2 ligand interacted
with TLR2. CaCl2-induced vascular injury resulted in a time-
dependent increase of HMGB1 expression (Fig. 5D), and blocking
TLR2-suppressed HMGB1 expression (Fig. 5E). Additionally, the
expression of HSP70 and S100A8 was increased, and targeting of
TLR2 reduced CaCl2-stimulated expression of these DAMPs in
aneurismal tissue measured by immunostaining (Fig. S1A and C in
Supporting information) and Western blot (Fig. S1B and D).3.5. Blocking TLR2 reduced the inﬁltration of inﬂammatory cells
and cytokines in vascular tissue
CaCl2 stimulated an increased CD11b
þ macrophage and CD4þ T
cell inﬁltration in aortic tissue, mainly in the outer aortic wall
(Fig. S2A and B). Moreover, the levels of MCP-1, TGF-β1, IL-10,
IL-6, IFN-γ and IL-17 A (Figs. S2C, D and S3A) were increased.
The phosphorylation of transcription factors, including NF-κBp65,
AP-1 (c-Jun, Fig. S3B), and STAT1/3 (Fig. S3C), were up-
regulated in CaCl2-damaged aortic tissue. However, systemic
administration of TLR2ab reduced the inﬁltration of inﬂammatory
cells and the expression of cytokines, as well as the activation of
these transcription factors. These data suggest that TLR2 signaling
has a crucial role in chronic inﬂammation in CaCl2-induced AAA.
Figure 2 Targeting TLR2 protects mice from the development of AAA. The CaCl2-induced AAA mice were immediately treated with the
indicated agents for 6 weeks. (A) A representative photograph of aortas showed that doxycycline and TLR2ab decreased the maximal external
aortic diameters (n¼12–15/group). (B) A representative ultrasound image of aortas (arrows indicate the aorta lumen), and histological studies of
AAA. (C) H&E stains of cross sections of aorta (top), local lesions (middle) and VVG stains for elastin (bottom). (D) Quantitative elastin content
analysis is shown as the percentage of the surface area occupied by elastic ﬁbers stained with VVG. (E) Internal aortic diameter was reduced by
TLR2ab, as indicated by morphometry using H&E staining of cross sections of the aorta (middle panel of C). Arrowheads indicate elastic lamella
(n¼8/group). Data are means7SD. ##Po0.01, ###Po0.001, compared to sham group. nPo0.05, nnPo0.01, compared to CaCl2 group.
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Figure 3 Targeting TLR2 reduces AAA lesions in vascular tissue of CaCl2-induced AAA. (A and B) Blocking TLR2 attenuated the expression
(A) and activities of MMP-2/9 (B) in the CaCl2-injured vascular tissue (n¼6). (C and D) CaCl2 stimulated a time-dependent increase in α-SMA
expression in vascular tissue (n¼5/time point/group) and targeting TLR2 decreased the expression of α-SMA (n¼6). (E) Targeting TLR2 reduced
the content of collagen I/III in aneurismal tissue stained by picrosirius red (n¼8). Data are means7SD. #Po0.05, ##Po0.01, ###Po0.001,
compared to sham group. nPo0.05, nnPo0.01, nnnPo0.001, compared to CaCl2 group.
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formation
To determine the relationship between TLR2 activation and AAA
pathogenesis, an established Ang II-induced AAA model was
generated in Apoe / mice. We found that a four-week infusion
of Ang II in Apoe / mouse resulted in the formation of
suprarenal aortic aneurysm (Fig. 6A). Blocking TLR2 signiﬁcantly
not only decreased animal death from ruptured aortic aneurysm
compared to the untreated AAA animals (2/16 versus 10/24,Po0.03; Fig. 6B), but reduced the incidence rate of AAA (7/16
versus 20/24, Po0.01), including type I-IV AAA, as indicated
previously (Fig. 6C). There was also a decrease in the maximal
aortic diameter in TLR2ab-treated mice compared to the mice
infused with Ang II alone (1.5370.35 versus 2.1670.39,
Po0.01; Fig. 6D). Furthermore, blocking TLR2 reduced the
activity of MMP-2 in the aortic tissues collected from the thoracic
aorta, suprarenal and infrarenal aorta and MMP-9 in all selected
aortic parts (Fig. 6E). Infusion of Apoe / mice with Ang II
enhanced the aortic lumen and wall thickness, resulted in the
Figure 4 Targeting TLR2 results in the regression of established AAA, and TLR2 deﬁciency protected mice from CaCl2-induced AAA. (A)
AAA animals were treated with TLR2ab for six weeks. Representative photographs of aortas from sham-treated mice and mice treated with saline
or TLR2ab (n¼10/group). (B) The CaCl2-induced AAA was generated in WT or Tlr2 / mice. Representative photographs of aortas from sham-
and CaCl2-treated WT mice and Tlr2
 / mice (n¼4/group). (C) The morphometric analysis was conducted for the maximal external and internal
diameters of aortas from sham or AAA mice treated with indicated agents (n¼10/group). (D) Tlr2 / mice showed a reduction in the maximal
external and internal diameters of aortas compared to WT mice (n¼8/group). (E and F) Histological analysis of cross sections of aorta was
performed with VVG and H&E staining. The elastin content was evaluated as the percentage of elastic ﬁbrous area stained with VVG. Arrowheads
indicate elastic lamella. Data are means7SD. ##Po0.01, ###Po0.001, compared to sham group. nPo0.05, nnPo0.01, compared to CaCl2 group.
TLR2 and abdominal aortic aneurysm 183degradation of elastin and deposition of extracellular matrix
(Fig. 6F), and promoted thrombus and inﬂammatory inﬁltration
in the aortic wall, as reported27. However, TLR2 blocking
protected from the destruction of elastic media and inhibited the
aortic expansion. Importantly, antagonism of TLR2 activity
signiﬁcantly reduced the Ang II-induced ROS production in
vascular tissue (Fig. 6F). Moreover, blocking TLR2 activity
attenuated inﬂammatory responses (Fig. S4), inhibited the phos-
phorylation of c-Jun N-terminal kinase (JNK), NF-κBp65, AP-1
and STAT1/3 in Ang II-induced AAA (Fig. S5). These data
demonstrate that the therapeutic efﬁcacy of TLR2 blocking against
the formation of AAA is independent of the animal models.4. Discussion
Our studies indicate that the innate immune receptor TLR2 plays an
essential role in the development and progression of AAA. Our
ﬁnding is supported by the following facts. First, the expression of
TLR2 and its endogenous ligands were up-regulated in human
aneurysm compared to control aortic tissue. Moreover, an enhanced
interaction between TLR2 and its ligand has been identiﬁed in
human AAA tissue, and blocking TLR2 in vitro attenuated TLR2-
mediated expression or activation of inﬂammatory factors andMMP-2/9 in AAA vascular tissue. Second, functionally or geneti-
cally blocking TLR2 attenuates AAA formation and causes
established AAA regression through attenuating the CaCl2- or
Ang II-enhanced MMP-2/9 activation and vascular remodeling.
Third, CaCl2- or Ang II-induced vascular injury and inﬂammatory
response promoted the expression of TLR2 and several endogenous
TLR2 ligands in aortic tissue. Blocking TLR2 decreased the
expression and interaction of TLR2 with its endogenous TLR2
ligands, and thus, interrupted the positive feedback loop between
TLR2 activation and inﬂammatory response. Fourth, blocking
TLR2 attenuated the recruitment of CD11bþ macrophages and
CD4þ T cells, expression of inﬂammatory factors, and activation of
transcription factors NF-κB, AP-1 and STAT1/3. Indeed, TLRs
expressed on or in human blood vessels have been found to mediate
selective immune responses and impose vessel-speciﬁc risk for
inﬂammatory vascular disorders12; the interactions between oxi-
dized lipoproteins and TLRs promote the development of athero-
sclerosis through the initiation of a sterile inﬂammatory response28.
Aoyama et al.29 report recently that TLR2 plays a fundamental role
in periodontal bacteria-accelerated AAA development. These
authors and we obtained similar results regarding the role of
TLR2 signaling in the regulation of AAA development by using
different animal models of AAA. Moreover, because our work
demonstrates that targeting TLR2 by an anti-TLR2 antibody induces
Figure 5 Targeting TLR2 attenuates expression of TLR2 and endogenous ligands in CaCl2-injured vascular tissue. (A) A time-dependent
increase of TLR2þ cells was found in CaCl2-injured vascular tissue (n¼5/time point/group). Targeting TLR2 reduced TLR2þ cells in adventitia (6
weeks, n¼8; 12 weeks, n¼10). (B) TLR2þ cells colocalized with CD11bþ macrophages in adventitia. DNA (top left, DAPI, blue); TLR2 (top
right, green); CD11b (bottom left, red); merge of TLR2, CD11b and DNA (bottom right); yellow arrowheads indicate TLR2þ/CD11bþ/adventitial
macrophages. (C) Colocalization (yellow) of HMGB1 (red) and TLR2 (green) was detected by immunoﬂuorescence (arrowheads). (D) A time-
dependent increase in HMGB1 expression was found in CaCl2-injured vascular tissue (n¼5/time point/group). (E) Blocking TLR2 attenuated
HMGB1 expression (n¼6). Data are means7SD. #Po0.05, ##Po0.01, ###Po0.001, compared to sham group. nPo0.05, nnnPo0.001, compared
to CaCl2 group.
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development of therapeutics against AAA.
Two in vivo AAA models were utilized for studying the role of
TLR2 activity in the development and progression of AAA.
Periarterial application of CaCl2 or infusion of Ang II is a
convenient and reliable model for induction of AAA in mice30.
Underlying mechanisms for the models are mainly due to the
accumulation of intracellular calcium and free radicals after
exposure to a high concentration of calcium or Ang II, which
are crucial for initiating inﬂammation to cause severe vascularinjury and tissue necrosis31. The injured or necrotic vascular tissue
liberates several intracellular factors functioning as DAMPs to
stimulate PRRs, such as TLR2, on the immune and residue cells to
lead to a chronic inﬂammation in vascular tissue. This DAMP/
TLR2 interaction–induced chronic inﬂammation is crucial in
maintaining a persistent activation of MMPs, extracellular matrix
degradation and ﬁbrosis, apoptosis of vascular smooth muscle, and
vascular remodeling in AAA24,32. According to Matzinger’s
‘danger’ mode, the crucial event controlling the initiation of
inﬂammation by Ang II or calcium was not infection, but the
Figure 6 Targeting TLR2 protects against Ang II-induced AAA formation. AAA was generated by infusion of Ang II (1000 ng/kg/min) in
Apoe / mouse. (A) Typical suprarenal aneurysms were induced by Ang II (arrows). (B) Targeting TLR2 reduced animal death from Ang II-
induced aneurysm rupture. Survival rate was analyzed by Kaplan-Meier. (C) Targeting TLR2 reduced the incidence of AAA. (D) Maximal
abdominal aortic diameter in Apoe / mice with Ang II infusion. (E) MMP-2/9 activities were evaluated with gelatin zymography in aortic arch
(a), thoracic (t), suprarenal (s) and infrarenal aorta (i) from the Apoe / mice infused with Ang II. The qualitative analysis was summarized from
four separate experiments. (F) Representative H&E staining, VVG, picrosirius red and dihydroethidium (DHE) for detecting ROS in the aortic
tissue. Data are means7SD. #Po0.05, ##Po0.01, compared to sham group. nPo0.05, nnPo0.01, compared to Ang II group.
TLR2 and abdominal aortic aneurysm 185production of danger signals from stressed, damaged, and/or dying
cells in the local tissue33. Indeed, recent studies clearly indicate
that the endogenous triggers are equally effective at activating a
reparative and protective response, including the activation of the
immune system through interaction with PRRs such as TLRs34.
Satoh et al.35 demonstrated that Ang II increases the expression of
the TLR ligand cyclophilin A in smooth muscle and that
cyclophilin A mediates Ang II-induced AAA formation by
inducing ROS accumulation, recruiting inﬂammatory cells and
activating MMP-2. An increase in the elastin content of aortic
tissue in AAA mice treated with an anti-TLR2 antibody indicate
that blocking TLR2 signaling attenuates the CaCl2-induced elastin
degradation by inhibiting inﬂammation and particularly, MMP-2/9
enzyme activity, and also promotes a regenerative and scarless
repair in AAA vascular tissue36. It needs pointing out that several
DAMPs released from damaged tissues including small HSPs and
binding immunoglobulin protein (bip) display anti-inﬂammatory
response or favor the resolution of inﬂammation that are named as
RAMPs8,9. However, because the study regarding how these
DAMPs can act as the RAMPs is in its infancy, further experi-
ments are necessary to explore how these RAMPs interact with
what PPR to negatively regulate inﬂammation and promote
immunological homeostasis.
Blocking of TLR2 provides a tremendous protective effect against
animal death from the ruptured aortic aneurysm caused by Ang II.These results clearly indicate that chronic blockade of TLR2 activity
diminishes Ang II-induced inﬂammation, reverses a massive destruc-
tion of elastin and promotes the reconstruction of the aneurysm wall.
However, because inhibition of matrix degradation seems insufﬁcient
to result in the regression of AAA, other mechanisms may involve the
reconstruction of the aneurysm wall by blocking TLR2. Indeed,
TLR2 blocking attenuates inﬂammation and tissue ﬁbrosis23,
while less ﬁbrosis before surgery may enable faster regression
after surgery in patients with aortic stenosis37. Using TLR2- and
TLR4-neutralizing antibodies, we have recently demonstrated that
blocking TLR2 attenuates the development of bleomycin- and silica-
induced pulmonary ﬁbrosis, but blocking TLR4 promotes the
development of pulmonary ﬁbrosis23,38. We also found that blocking
TLR2 attenuates the tumor metastasis, but blocking TLR4 promotes
tumor metastasis24,39. Similarly, blocking TLR2 prompts but blocking
TLR4 attenuates the resolution of chronic inﬂammation and protects
against or aggravates doxorubicin-induced cardiovascular remodeling
and dysfunction15. These observations indicate that TLR2 or TLR4
signaling has a differentiate regulation in the pathogenesis of
tissue ﬁbrosis, cancers and cardiomyopathy. Interestingly, we have
found that targeting TLR4 can attenuate the progression of AAA in
CaCl2-induced AAA through a similar mechanism to current study
(unpublished observation).
However, Owens et al.40 reported recently that MyD88
deﬁciency attenuates Ang II-induced abdominal aortic aneurysm
Huimin Yan et al.186formation independent of signaling through toll-like receptors 2
and 4. This ﬁnding seems conﬂicting with the ﬁnding in the
current study. Nevertheless, the AAA model used by these authors
was induced by a deﬁciency of adaptor molecule MyD88 in
leukocytes whereas AAA model used by current study was
induced by a deﬁciency of either TLR2 or TLR4 in whole animal.
Therefore, these different observations reminder us how TLR2
activity interferes with the capacity of vascular repair and
regeneration and how blocking TLR2 promotes the reconstruction
of aneurysm wall from the injured AAA are still open and need
further investigation.
In summary, our study may have signiﬁcant clinical implica-
tions. In contrast to several therapeutic agents, such as inhibitors of
MMP and anti-inﬂammatory agents16,41, which can promote a
regression of AAA, targeting TLR2, which is a membrane receptor
and contributes to multiple aspects in AAA development, will
probably provide greater therapeutic beneﬁt and easy access.
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